Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies

Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug testing on primary CLL cells and identified synerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Melvold, Katrine, Giliberto, Mariaserena, Karlsen, Linda, Ayuda‐Durán, Pilar, Hanes, Robert, Holien, Toril, Enserink, Jorrit, Brown, Jennifer R., Tjønnfjord, Geir E., Taskén, Kjetil, Skånland, Sigrid S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895453/
https://www.ncbi.nlm.nih.gov/pubmed/34861096
http://dx.doi.org/10.1002/1878-0261.13153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895453/
https://www.ncbi.nlm.nih.gov/pubmed/34861096
http://dx.doi.org/10.1002/1878-0261.13153

Ejemplares similares